Welcome to our dedicated page for Protagonist Therapeutics news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics stock.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to discover and develop novel peptide-based drugs. The company's primary focus is on creating first-in-class oral targeted therapies that inhibit biological pathways currently addressed by injectable antibody drugs. This innovative approach aims to treat significant unmet medical needs, particularly in the areas of inflammatory bowel disease (IBD) and other autoimmune diseases.
Protagonist's lead peptide product candidates, PTG-100 and PTG-200, are designed to transform treatment paradigms for conditions such as ulcerative colitis and Crohn's disease. PTG-100, an oral peptide alpha-4-beta-7 integrin antagonist, is in a global Phase 2b clinical trial for moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral interleukin-23 receptor antagonist, is also progressing through clinical trials.
Another key asset, JNJ-2113 (formerly PN-235), achieved primary and secondary endpoints in the Phase 2b FRONTIER 1 trial for moderate-to-severe plaque psoriasis. This drug is part of an extensive clinical development program, including multiple Phase 3 studies under the ICONIC program. JNJ-2113 is also being evaluated in a Phase 2b ANTHEM-UC study for ulcerative colitis.
Protagonist's pipeline also includes Rusfertide (PTG-300), an injectable hepcidin mimetic currently in Phase 3 development for polycythemia vera. The REVIVE Phase 2 study demonstrated that rusfertide effectively maintains hematocrit control and reduces the need for phlebotomies in patients.
The company has established significant partnerships to further its clinical programs. Notably, Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead candidates, expanding its reach and impact in the biopharmaceutical landscape.
Protagonist continues to drive innovation with its ongoing discovery efforts, aiming to develop additional oral peptides targeting validated biological pathways. With a robust pipeline and strategic collaborations, Protagonist Therapeutics is poised to make substantial contributions to the treatment of autoimmune and hematological diseases.
Protagonist Therapeutics (PTGX) announced plans to initiate a global Phase 3 clinical trial for rusfertide (PTG-300), targeting polycythemia vera (PV). The FDA provided key feedback, and the EMA expressed support for its clinical development plan. The Phase 3 study will enroll 200-250 adult participants, focusing on the proportion achieving response defined by hematocrit control. Secondary endpoints will include symptoms and phlebotomy frequency. The trial aims to address unmet needs in PV treatment, paving the way for future drug applications in the U.S. and Europe.
Protagonist Therapeutics (Nasdaq: PTGX) reported its financial results for Q4 2020, highlighting significant growth in its pipeline. The company received orphan drug and Fast Track designations for rusfertide in polycythemia vera (PV), affecting approximately 100,000 patients in the U.S. Protagonist aims to finalize its clinical development plan for rusfertide by mid-2021. The company raised $255 million through various public offerings in 2020, ending the year with $307.8 million in cash and equivalents. However, it reported a net loss of $66.2 million for the full year 2020.
Protagonist Therapeutics (Nasdaq: PTGX) will host a conference call on March 10, 2021, at 4:30 PM ET to discuss its Q4 and full year 2020 financial results. The call can be accessed via phone at 1-844-515-9178 (U.S.) or 1-614-999-9313 (International), with conference ID #: 7756175. A live webcast will also be available on the company's website. Protagonist is developing several peptide-based therapeutics, including PTG-300 and PTG-200, currently in various stages of clinical trials.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the virtual H.C. Wainwright Global Life Sciences Conference from March 9 to 10, 2021. CEO Dinesh V. Patel, Ph.D., will engage in a fireside chat on March 9, starting at 7:00 a.m. EST, with a subsequent opportunity for one-on-one meetings with investors. A webcast of the event will be available for 90 days. Protagonist is advancing multiple peptide-based therapeutics, including PTG-300 and PTG-200, targeting various conditions such as polycythemia vera and Crohn's disease.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) announced the issuance of an inducement award to Jami Taylor, newly appointed Vice President of Corporate Affairs, on February 26, 2021. The award includes an option to purchase 50,000 shares at an exercise price of $23.57, the closing price on the grant date. The shares vest over four years. This grant is part of the Amended Inducement Plan adopted on May 29, 2018, reflecting the company's commitment to attract top talent. Protagonist is focused on developing peptide-based therapeutics for significant unmet medical needs.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) will participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference from February 22 to 26, 2021. Dinesh V. Patel, Ph.D., President and CEO, is scheduled for a fireside chat on February 24, 2021, at 10:40 a.m. EST. The event will be available for live and archived viewing on the company’s website. Protagonist, based in Newark, California, focuses on innovative peptide-based therapeutics, with several candidates in clinical trials for conditions like Crohn's disease and polycythemia vera.
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) announced the issuance of an inducement award to Dr. Paula O'Connor, recently appointed as Senior Vice President of Clinical Development. This award includes an option to purchase 75,000 shares of the company’s common stock at an exercise price of $20.71, the closing price on January 29, 2021. The award is designed as a recruitment incentive, with shares vesting over four years. Protagonist Therapeutics focuses on developing peptide-based therapeutics for various medical conditions, with several candidates currently in clinical trials.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced that CEO Dinesh V. Patel, Ph.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. EST. The event will be available via live and archived webcast on their website. Protagonist is a clinical-stage biopharmaceutical company focusing on peptide-based therapeutics, with candidates like PTG-300 and PTG-200 in Phase 2 trials for various conditions, including polycythemia vera and Crohn's disease.
Protagonist Therapeutics (Nasdaq: PTGX) has initiated a Phase 1 study for PN-235, an oral IL-23 receptor antagonist. This study, involving about 100 healthy volunteers, aims to assess the drug's safety and pharmacokinetics. PN-235 is the first oral candidate from a collaboration with Janssen Biotech. The study includes ascending doses and a solid dose comparison, focusing primarily on safety. Protagonist anticipates Phase 1 results in 2021, with potential applications in various diseases. The collaboration allows Protagonist to earn milestone payments as Janssen handles later development phases.
Protagonist Therapeutics (Nasdaq: PTGX) completed an underwritten public offering of 5,476,189 shares of common stock at a public price of $21.00 per share, raising approximately $115.0 million in gross proceeds. This includes 714,285 shares sold due to the underwriters' full exercise of their 'green shoe' option. The shelf registration statement was filed with the SEC on December 10, 2020. J.P. Morgan, SVB Leerink, Piper Sandler, and BMO Capital Markets managed the offering.
FAQ
What is the current stock price of Protagonist Therapeutics (PTGX)?
What is the market cap of Protagonist Therapeutics (PTGX)?
What is Protagonist Therapeutics' main focus?
What are PTG-100 and PTG-200?
What is JNJ-2113?
What is rusfertide (PTG-300)?
Who are Protagonist's collaboration partners?
What recent achievements has Protagonist announced?
What is Protagonist's proprietary technology platform?
What are the latest developments in Protagonist's clinical trials?
What is the status of the rusfertide Phase 3 VERIFY trial?
Where can I find more information about Protagonist's drug candidates and clinical studies?
